Navigation Links
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
Date:5/11/2009

BRIDGEWATER, N.J., May 11 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that it has acquired from biotechnology company Antisoma plc the U.S. commercial rights to Oforta(TM) (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug. Oforta is currently approved in the United States for use as a second-line therapy to treat adults with B-cell CLL.

"We are extremely pleased to add Oforta to our existing oncology portfolio, and believe it represents an exciting opportunity for sanofi-aventis U.S.," said John Harrington, Vice President and Head of the Oncology Business Unit at sanofi-aventis U.S. "Sanofi-aventis is a company committed to identifying and exploring new treatment options for patients facing serious diseases, such as CLL. This agreement further supports our efforts to help patients and complements our strong heritage of providing therapies to treat cancer."

Antisoma currently licenses certain rights and purchases Oforta from Bayer Schering Pharma AG. As part of this transaction, sanofi-aventis U.S. will acquire these agreements.

Oforta is a nucleoside analogue designed to prevent cancer cells from dividing by inhibiting DNA synthesis. Oforta was granted accelerated review and later received approval from the U.S. Food and Drug Administration (FDA) in December 2008 to treat adult patients with B-cell CLL whose disease has not responded to, or has progressed during or after treatment with at least one standard alkylating-agent containing regimen. Oforta is an orally administered tablet formulation of fludarabine phosphate.

About Oforta

Oforta is indicated as a single agent for the treatment of adult patients with B-cell CLL whose disease has not responded to, or has progressed during or after treatment with at least one standard alkylating-agent containing regimen. Studies demonstrating clinical b
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
2. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
3. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
6. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
8. Cord Blood America to Acquire or Build Its Own Stem Cell Laboratory
9. ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center
10. Sigma-Aldrich Acquires Sigal Ltda and Expands Operations in Chile
11. Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Fertility Associates ... Donor Egg Bank USA , a network of more ... Through this partnership, patients have fast access to a ... vitro fertilization, IVF . Fertility Associates of Memphis is ... this fertility treatment option. , Dr. William Kutteh ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
(Date:12/19/2014)... DUBLIN , Dec. 19, 2014 Research ... announced the addition of the "Technology Innovations ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Innovations in Smart Fabrics" offers a detailed assessment ... Key Findings: 1. ...
Breaking Biology Technology:Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Technology Innovations in Smart Fabrics (Technical Insights) 2
... WOODCLIFF LAKE, N.J., Dec. 27 - Eisai Co.,Ltd. ... Eisai Inc.,(Headquarters: New Jersey, Chairman and CEO: Hajime ... against Mutual Pharmaceutical Co.,Inc. and United Research Laboratories, ... abbreviated new drug application (ANDA),to the U.S. Food ...
... Resigns as President and CEO -, DALLAS, Dec. ... today that current Chairman Jeffrey B.,Davis has been appointed ... resigned as President and CEO of the Company for ... of Directors., "I believe that Access has an ...
... ROCK, Colo., Dec. 24 AspenBio Pharma,Inc. (Nasdaq: ... of novel drugs and diagnostics for animals and humans, ... of existing and,new investors. $18.2 million in gross proceeds ... of the company,s common stock., Net proceeds to ...
Cached Biology Technology:U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing 2U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing 3Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO 2Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO 3AspenBio Pharma Closes $18.2 Million Private Placement of Common Stock 2AspenBio Pharma Closes $18.2 Million Private Placement of Common Stock 3
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming ... evident than at international borders. Over the past ... have allowed veteran travelers to self process through ... (APC) Kiosks at an increasing number of airports, ... According to Maxine Most , ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... papers that have been recently published in Geophysical Research ... Earth ( JGR-B ) and Journal of Geophysical ... 1. An earthquake in Japan caused large waves in Norwegian ... in Ohio, 3. The Arctic is especially sensitive to black ...
... Johns Hopkins have uncovered a protein switch that can ... depending on the signals it detects. Its dual role ... network of signals that shapes our brain,s circuitry, the ... the July 31 issue of the Journal of ...
... A strain of bacteria that causes skin and soft tissue ... study to be published in mBio , the online ... who conducted the genetic analysis of strains of Staphylococcus ... to methicillin after they crossed over into humans around forty ...
Cached Biology News:AGU journal highlights -- Aug. 13, 2013 2AGU journal highlights -- Aug. 13, 2013 3AGU journal highlights -- Aug. 13, 2013 4AGU journal highlights -- Aug. 13, 2013 5AGU journal highlights -- Aug. 13, 2013 6AGU journal highlights -- Aug. 13, 2013 7AGU journal highlights -- Aug. 13, 2013 8Newly discovered 'switch' plays dual role in memory formation 2MRSA strain in humans originally came from cattle 2MRSA strain in humans originally came from cattle 3
Kinase Buffer can be used to assay protein kinase activity...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Biology Products: